Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells 140,488 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 140,488 shares of the stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $1.22, for a total value of $171,395.36. Following the completion of the transaction, the insider directly owned 6,007,122 shares in the company, valued at approximately $7,328,688.84. This trade represents a 2.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Thursday, November 6th, Ansbert Gadicke sold 54,452 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total value of $65,886.92.
• On Wednesday, November 5th, Ansbert Gadicke sold 47,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $58,499.00.
• On Monday, November 3rd, Ansbert Gadicke sold 94,063 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total value of $121,341.27.
• On Friday, October 31st, Ansbert Gadicke sold 114,044 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.28, for a total value of $145,976.32.
• On Thursday, October 30th, Ansbert Gadicke sold 86,936 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.43, for a total value of $124,318.48.
• On Wednesday, October 29th, Ansbert Gadicke sold 134,240 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total value of $208,072.00.
• On Tuesday, October 28th, Ansbert Gadicke sold 69,068 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.64, for a total value of $113,271.52.
• On Monday, October 27th, Ansbert Gadicke sold 72,709 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.72, for a total value of $125,059.48.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ HOWL traded down $0.02 during mid-day trading on Thursday, hitting $1.20. The stock had a trading volume of 647,728 shares, compared to its average volume of 891,846. The company has a debt-to-equity ratio of 0.73, a quick ratio of 5.30 and a current ratio of 3.87. The company has a 50 day moving average of $1.61 and a two-hundred day moving average of $1.32. Werewolf Therapeutics, Inc. has a twelve month low of $0.60 and a twelve month high of $2.41. The firm has a market cap of $58.25 million, a PE ratio of -0.74 and a beta of 0.72.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. Research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MPM Asset Management LLC grew its position in Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares during the period. MPM Bioimpact LLC grew its position in shares of Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after acquiring an additional 20,799 shares during the period. Bank of America Corp DE grew its position in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after acquiring an additional 25,882 shares during the period. Jane Street Group LLC acquired a new stake in shares of Werewolf Therapeutics during the 2nd quarter valued at about $409,000. Finally, Marshall Wace LLP acquired a new stake in shares of Werewolf Therapeutics during the 2nd quarter valued at about $113,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on HOWL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. JMP Securities cut their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. Bank of America cut their target price on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, August 25th. Finally, Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.